Kuopio University Hospital
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Kuopio University Hospital researchers are advancing care for patients with heart‑related conditions by testing innovative anticoagulant strategies and protective approaches after vascular injury.
- Atrial fibrillation and stroke prevention
- Comparative safety of new oral anticoagulants
- Management of vascular complications following subarachnoid hemorrhage
The work aims to improve outcomes for individuals at risk of stroke or systemic embolism while reducing bleeding complications.
Hemic and Lymphatic Diseases
Clinical investigations focus on blood‑borne malignancies, evaluating next‑generation immunochemotherapy for aggressive lymphoma.
- Diffuse Large B‑Cell Lymphoma treatment optimization
- Assessment of novel antibody‑drug combinations
- Balancing efficacy and tolerability in older patients
The goal is to determine whether pola‑R‑mini‑CHP can provide stronger disease control compared with standard regimens.
Neoplasms
The site’s oncology program explores cutting‑edge therapies for cancer, with a particular emphasis on improving survival for challenging tumor types.
- Innovative regimens for high‑grade lymphomas
- Integration of targeted agents into chemotherapy backbones
- Patient‑centered outcomes in cancer care
By testing pola‑R‑mini‑CHP, investigators hope to set new standards for treatment effectiveness in Diffuse Large B‑Cell Lymphoma.
Nervous System Diseases
Neuroscience research at the hospital examines brain protection after severe bleeding events, seeking methods to limit injury and enhance recovery.
- Aneurysmal subarachnoid hemorrhage management
- Neuroprotective properties of inhaled gases
- Long‑term neurological outcome measurement
The study investigates whether inhaled xenon can reduce brain damage and improve survival following subarachnoid hemorrhage.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 24 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 107 other sites in Finland
Therapeutic Area Benchmark — Finland
Select a therapeutic area to compare against other sites in Finland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Finland
Market Share
Country: Finland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Kuopio University Hospital
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Effect of xenon on brain injury, neurological outcome and survival in patients after aneurysmal subarachnoid hemorrhage | Turku University Hospital | Phase II | Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 24 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Prednisone | 2 | Unknown | 2020-08-18 | 2022-12-15 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.